Professor Rob Howard (UCL Psychiatry), Professor John Hardy and Professor Nick Fox (UCL Institute of Neurology) comment on the failure in late-phase effectiveness trials of solanezumab, a drug which had shown promise for treating Alzheimer's disease in early tests. , , ,Ìý